More NewsRead More
Hemispherx Biopharma Bolsters Manufacturing and Scientific Capabilities Through Key Consulting and Management Appointments
July 19, 2016
Hemispherx Outlines Key Elements of Strategic Growth Plan and Commitment to Transparency
July 14, 2016
Hemispherx Biopharma Enters into Settlement Agreements Dismissing All Pending Shareholder Derivative Litigation, Resolving Disputes with Insurance Carriers, and Obtaining Commitments of $3.5 Million i
June 08, 2016
Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, “Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)” in Expert Review of
June 07, 2016
Hemispherx Biopharma Obtains a Comprehensive Carter Omnibus Assignment of Intellectual Property
June 06, 2016
Hemispherx Biopharma Renews Sales, Marketing, Distribution and Supply Agreement with GP Pharm
May 31, 2016
UPDATE -- Hemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe
May 24, 2016
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here